Pancreatic triacylglycerol lipase and Alpha-amylase (PL/AMY)

Pancreatic triacylglycerol lipase (PNLIP) and alpha-amylase (AMY2A/B) are essential digestive hydrolases synthesized and secreted by the exocrine pancreas into the duodenum (UniProt P16233, P04746). Pancreatic lipase is responsible for the hydrolysis of the majority of dietary fats, converting triglycerides into absorbable 2-monoacylglycerols and free fatty acids (PubMed: 17472472). Alpha-amylase targets the alpha-1,4-glycosidic bonds in complex carbohydrates like starch, initiating their breakdown into simpler sugars such as maltose (PubMed: 22036625). These enzymes are significant therapeutic targets in the management of metabolic disorders; inhibiting lipase reduces lipid absorption to treat obesity, while inhibiting amylase slows carbohydrate digestion to manage postprandial hyperglycemia in type 2 diabetes (StatPearls: Obesity, Acarbose). Drugs such as orlistat covalently bind to the active site of lipase, while alpha-glucosidase inhibitors like acarbose also exhibit inhibitory activity against pancreatic amylase (PubChem CID 3034010, 41774). Clinical use of these inhibitors is often limited by gastrointestinal side effects, including steatorrhea and flatulence, resulting from the fermentation of undigested nutrients by colonic microbiota (PubMed: 10429875).

Other names

PNLIPAMY2AAMY2BSteapsin1,4-alpha-D-glucan glucanohydrolaseTriacylglycerol acylhydrolasePancreatic lipasePancreatic alpha-amylase

Inhibition of enzymatic hydrolysis of dietary lipids and complex carbohydrates in the gastrointestinal lumen to prevent their absorption into the systemic circulation.